In dermographometer-confirmed, antihistamine-refractory DPU, omalizumab was associated with a rapid clinical remission in almost all patients, typically within 24-48 hours, independent of baseline IgE and common comorbidities. Standardized pressure provocation testing provides objective confirmation of DPU and a pragmatic approach for diagnosis and real-world monitoring of therapeutic response in DPU. Given the open-label, uncontrolled design, these findings should be confirmed in larger multicenter controlled studies.
Koplin et al. (Thu,) studied this question.